Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Novel prime-boost combinations of attenuated mycobacterium

A technology for mycobacteria and mycobacterial antigens, which can be applied in the directions of drug combination, bacteria, antibody medical components, etc., can solve the problems of not providing cost-effectiveness and the like

Inactive Publication Date: 2009-05-13
AERAS GLOBAL TB VACCINE FOUND
View PDF6 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Existing processes are therefore far from providing a cost-effective and effective strategy for this

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel prime-boost combinations of attenuated mycobacterium
  • Novel prime-boost combinations of attenuated mycobacterium
  • Novel prime-boost combinations of attenuated mycobacterium

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0146] Example 1. Construction of recombinant BCG strains that overexpress TB antigens and escape endosomes

[0147] To generate strains that escape endosomes, we developed BCG1331 derivatives expressing perfringolysin O(Pfo), a cytolysin normally secreted by Clostridium perfringens, encoded by the pfoA gene (GenBank accession number CPE0163 ). PfoA mediates escape from phagosomes when expressed in Clostridium and in Bacillus subtilis (52). However, unlike Llo, PfoA is active at both pH 5.0 and pH 7.0 (52). To limit the cytotoxicity of Pfo, a mutant form of this protein with a G137Q substitution (PfoAG137Q) was used, since this strain has a short half-life in the host cell cytosol and is also capable of mediating endosomes over a wide pH range escape of (52).

[0148] In order to study the usefulness of PfoAG137Q, we constructed a recombinant BCG that secretes this protein and named it AFV102 (ie BCG1331 ureC::pfoAG137Q). The strain was constructed by allelic exchange with t...

Embodiment 2

[0163] Example 2. Optimization of Oral Recombinant BCG Vaccine Formulation and Dosage

[0164] Before testing a new two-component TB vaccine, studies were conducted to determine the optimal oral formulation and dosage. Groups containing 16 BALB / c mice were inoculated via gastric cannulation as shown in Table 5. 72 hours after inoculation, 3 mice per group were sacrificed and the number of viable AFV102 bacteria in intestine, Peyer's patch, lung and spleen were counted by the direct plate count method described above. This experiment shows that oral formulations containing Cera Vacx including gastric neutralizing components are more effective than formulations without them in their ability to deliver living organisms to mucosal tissues.

[0165] Six weeks after inoculation, 5 animals in each group were sacrificed and the immune responses to Rv3804c, Rv1886 and Rv0288 were measured by flow cytometric analysis. Briefly, mice were sacrificed by cervical dislocation and spleens w...

Embodiment 3

[0172] Example 3. Optimization of Vaccination Strategies

[0173] The purpose of this experiment was to optimize the prime-boost strategy of the candidate attenuated mycobacterial vaccine strain AFRO-1 (Example 1) in SPF male Hartley guinea pigs (250-300 grams). Therefore, 10 animals per group were vaccinated as shown in Figure 6 in order to evaluate prime-booster intervals of 10, 14 and 17 weeks.

[0174] Table 6. Guinea Pig Strategy Study Design

[0175] Group Trigger I

(Day 1) Initiate II

(week 3) Trigger III

(week 7) strengthen

(week 17) 1 salt water (id) - - 3 AFRO-1(id) - - AFRO-1(po) 4 - AFRO-1(id) - AFRO-1(po) 5 - - AFRO-1(id) AFRO-1(po) 6 - - - AFRO-1(po)

[0176] Initiate with 0.1ml of 10% glycerol containing 10 6 Dosing of cfu was performed by intradermal administration. Control mice received only 0.1 ml of 10% glycerol intradermally. Fourteen weeks after priming, guinea pigs were...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides vaccine compositions for effective induction of both mucosal and systemic immunity to pathogenic Mycobacterium species. Vaccination protocols are provided in which both parenteral and mucosal vaccine formulations are administered to a host. The parenteral and mucosal formulations comprise live, attenuated Mycobacteria.

Description

technical field [0001] In general, the present invention relates to methods of vaccinating a host against pathogenic mycobacteria. In particular, the present invention provides methods of vaccination wherein parenteral and mucosal formulations of live, attenuated mycobacteria are administered sequentially to a host, resulting in systemic vaccination against live, attenuated mycobacteria. and mucosal immune responses. Background technique [0002] Tuberculosis (TB) is a huge and deadly problem in developing countries, killing millions of people early in their lives each year. It is the leading cause of death in HIV-infected individuals (11, 15, 16, 43, 44) and women of reproductive age (61, 63, 65). The World Health Organization (WHO) estimates that there are 8 million new cases of TB and 2 million deaths from TB each year (5, 24). Among infectious diseases, only HIV and diarrheal diseases kill more people. [0003] In 1993, WHO designated TB as a global public health eme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/04C12Q1/00C12N1/20
CPCA61K2039/522A61K2039/545A61K2039/54A61K39/04A61K2039/523A61K39/21A61K39/295A61K2039/541A61K2039/6006A61P37/04
Inventor 大卫·迈克尔·霍恩杰拉尔德·C·萨多夫
Owner AERAS GLOBAL TB VACCINE FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com